Study of MLN8237 in Combination With Irinotecan and Temozolomide

Completed · Phase 1/Phase 2

Conditions studied: Neuroblastoma

In brief

The goal of the first part of this clinical trial (Phase I portion) is to study the side effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 when added to standard chemotherapy drugs, irinotecan and temozolomide. The goal of the second part of this clinical trial (Phase II portion) is to learn how many children and young adults show improvements in their neuroblastoma when treated with the combination of MLN8237, irinotecan, and temozolomide.

Key facts

Study ID
NCT01601535
Run by
New Approaches to Neuroblastoma Therapy Consortium
People needed
54
Starts
2012-05-01
Expected to finish
2018-07-25
Last updated by the study team
2019-07-31

Who can join

Age: 1 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.